

# Genotyping Guidelines for Co-testing (Pap + HPV)

**References:** **1.** ASCCP. Algorithms: Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Published 2013. Accessed May 31, 2019. **2.** ACOG. Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. 2016;128(4):e121. **3.** de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol.* 2010;11(11):1048-1056. **4.** Aptima HPV Assay [package insert]. AW-12820. 003. San Diego, CA; Hologic, Inc. **5.** Aptima HPV 16 18/45 genotype assay [package insert]. AW-12821. 003. San Diego, CA; Hologic, Inc.

[hologic.com](http://hologic.com) | [diagnostic.solutions@hologic.com](mailto:diagnostic.solutions@hologic.com) | 888.484.4747

PB-00771-001 Rev. 001 © 2019 Hologic, Inc. All rights reserved. Hologic, Aptima and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to [diagnostic.solutions@hologic.com](mailto:diagnostic.solutions@hologic.com).

**Aptima® HPV**  
Assay

**Aptima® HPV 16 18/45 Genotype**  
Assay

# Managing Abnormal HPV Results

## Genotyping Guidelines<sup>1</sup>



“Guidelines support the use of HPV genotyping for women aged 30–65 years who are undergoing cotesting and have negative Pap test results but positive high-risk HPV test results.”<sup>2</sup>

- ACOG


Cytology-negative and HPV-positive Co-test results occurred in 3.7% of women 30 and older.<sup>2</sup>



HPV types 16, 18, and 45 are associated with up to 94% of HPV-related cervical adenocarcinomas.<sup>3</sup>

The Aptima® HPV assay and the 16 18/45 genotype assay can be run off of the **same patient sample**.<sup>4,5</sup>

# Triage Guidelines for Abnormal HPV Results<sup>1</sup>



Genotyping is **ONLY** recommended for women between the ages of 30-65 with negative Pap test results but positive HPV test results.

<sup>\*</sup>Co-testing follow-up intervals vary based on results, refer to ASCCP guidelines for specific follow-up intervals.